The Advisory Committee on Immunization Practices (ACIP) recently held a meeting on June 25–26. During the meeting, ACIP voted on the following topics:

• Merck’s RSV Monoclonal Antibody Enflonsia™ – The incorporation of Merck’s new monoclonal antibody Enflonsia™ was recommended by the committee for prevention of RSV. Enflonsia™ is administered as a single dose, regardless of body weight, to protect infants younger than eight months born during or entering their first respiratory syncytial virus (RSV) season. Click here for more information on Merck’s Enflonsia™.

• Enflonsia™ is billed under CPT code 90382 - Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use. As a reminder, we recommend checking with your major payers to ensure adequate payment is in place before incorporating new immunizations into your schedule. Typically, we begin seeing payments for newly approved immunizations 90 days after the CDC Director has confirmed the ACIP’s recommendations.

• This new immunization is also now part of the CPP portfolio, offering a discount to those members already participating in the CPP/Merck contract. If you would like to enroll with the CPP/Merck discount or need updated pricing, please contact the CPP office at cpp@nationwidechildrens.org. 

• Influenza Vaccines – For the first time since 2017–2018, the 2024–2025 influenza season was classified as “high severity” across all indicators, with an estimated 56 million illnesses, 25 million medical visits, and 770,000 hospitalizations. For the 2025-2026 flu season, the ACIP recommends that all children aged six months and older, pregnant women and adults should receive a flu vaccine that is thimerosal-free. Thimerosal is an ethylmercury-based preservative commonly used in multi-dose vaccine vials to prevent bacterial/fungal contamination. 

• Sanofi anticipates having sufficient supply of Fluzone® available in pre-filled syringes so that anyone who pre-booked Fluzone® multi-dose vials and would prefer preservative free pre-filled syringes can reach out to Sanofi to change your reservation. Please contact Sanofi’s customer service department at 1-800-VACCINE (800-822-2463) to discuss modifications to your order. If you did not order any Fluzone® multi-dose vials, there will be no changes to your reservation and there is no action required at this time.

• Seqirus is automatically converting any pre-booked multi-dose vials of Afluria® or Flucelvax® to pre-filled syringes at no cost to the customer. There is nothing CPP members need to do. If you have any questions, reach out to Seqirus customer service at 855-358-8966.

Additional flu vaccine updates include:



• Sanofi’s Flublok® is now FDA approved for use in patients aged nine and older.
• AstraZeneca’s FluMist® is now FDA approved for self or caregiver administration.

To learn more about the fall season respiratory codes click here.

Pfizer COVID-19 Vaccine Update

Pfizer will continue shipping the 2024–2025 COVID-19 vaccine formula through August 8, 2025, while preparing to launch the updated 2025–2026 version targeting the FDA-preferred LP.8.1 strain. Vaccines expiring before September 1, 2025 are eligible for return between August 1–September 15, 2025. Those expiring later qualify for full credit returns through November 1, 2025. Updated storage and expiry labeling guidance is also available. Click here to learn more.

CDC Updates: VFC Vaccine Stocking Rules

The CDC has eased stocking requirements for Vaccines for Children (VFC) providers, no longer mandating them to stock all vaccines for privately insured children. This change especially impacts birthing hospitals and aims to improve access to RSV immunization for newborns. Read more on this from the AAP News here.